Objectif
Europe has one of the highest prevalence of insulin dependant diabetes (IDDM), with more than one million patients. Treatment modalities are far from optimal, and chronic IDDM has devasting vascular complications with staggering costs for the Community. Six European groups and a research-based biotechnology firm with expertises in the field diabetology and immunology, here together design a novel approach to develop new clinically applicable tools to predict IDDM development. These tools are based on the new insight that monocyte-derived cells play key roles in the aetiology and pathogenesis of IDDM. Major effort will be directed towards DNA micro-array methods for discovering molecules in monocytes specific for the prediabetic state. From this, monocyte-related tests for the prediction of IDDM wil are created. The (pre-) diabetes specific molecules will also have great potential as basis for novel therapies in the prevention of IDDM.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
3000 DR ROTTERDAM
Pays-Bas